12 Best Relay Therapeutics Alternatives & Competitors (2026)

Schrödinger provides a comprehensive computational chemistry platform used by pharma and biotech for structure-based drug design and molecular simulation. Its licensing model allows direct purchase by research teams rather than requiring large external partnerships. Compared with PostEra, Schrödinger offers deeper physics-based modeling and broader target-class coverage but less emphasis on end-to-end clinical collaboration management.

Schrödinger provides a comprehensive computational chemistry platform used by pharma and biotech for structure-based drug design and molecular simulation. Its licensing model allows direct purchase by research teams rather than requiring large external partnerships. Compared with PostEra, Schrödinger offers deeper physics-based modeling and broader target-class coverage but less emphasis on end-to-end clinical collaboration management.

Schrödinger provides physics-based molecular modeling and simulation software widely used in drug discovery. Its platform emphasizes structure-based design and free-energy calculations rather than generative AI for peptide macrocycles. Compared with Menten AI, Schrödinger offers broader small-molecule and biologics tooling with established enterprise licensing but lacks Menten’s specialized de novo macrocycle generation validated at >90% hit rates for PPIs.

Schrödinger provides physics-based computational software for molecular modeling and drug design. Its platform excels at accurate binding predictions and lead optimization but typically requires more manual setup than Numerion Labs ML-driven superplatform. Pricing follows a subscription model aimed at large pharma and academic groups. While Schrödinger offers broad applicability, it lacks Numerion Labs explicit focus on immune-disease programs and unseen-molecule discovery.

Recursion applies machine learning to large-scale cellular imaging for phenotypic drug discovery across many targets. Its strength lies in rapid hypothesis generation from millions of experiments, yet it remains primarily cell-phenotype driven rather than RNA-sequence or splicing focused like Serna Bio. Pricing is typically partnership-based; teams seeking explicit RNA modulation may find Recursion broader but less specialized for translation targets.

Insilico Medicine runs an AI-driven pipeline from target discovery through clinical trials, with its own proprietary generative chemistry engine. It operates both partnered and internal programs, giving sponsors clearer IP terms than PostEra’s shared-collaboration approach. Its strength lies in rapid target-to-IND timelines across oncology and fibrosis.

Recursion applies machine learning to large-scale cellular imaging for phenotypic drug discovery across many targets. Its strength lies in rapid hypothesis generation from millions of experiments, yet it remains primarily cell-phenotype driven rather than RNA-sequence or splicing focused like Serna Bio. Pricing is typically partnership-based; teams seeking explicit RNA modulation may find Recursion broader but less specialized for translation targets.

Exscientia combines generative AI and active learning to design novel compounds and operates its own clinical-stage programs. Compared with Numerion Labs, Exscientia places heavier emphasis on end-to-end automation from target to clinic and maintains a larger disclosed pipeline. Its enterprise collaborations often involve milestone payments rather than pure software licensing.

Atomwise applies deep learning to structure-based virtual screening across billions of compounds. Its strength lies in rapid hit finding for diverse targets, while Numerion Labs highlights molecules unseen by others through broader chemical-space mapping. Atomwise primarily operates via research collaborations rather than self-serve software.

BenevolentAI integrates knowledge graphs with generative models to surface novel drug candidates and runs internal programs. Relative to Numerion Labs, it covers a wider range of disease areas beyond immune indications and relies more on curated biomedical data. Access is typically granted through strategic partnerships.

Generate Biomedicines uses generative models to create de novo proteins and antibodies. While powerful for biologics, it diverges sharply from Serna Bio's small-molecule RNA targeting strategy and multiplexed screening platform for intracellular translation and splicing control.